Trafalgar International (GCAN) Total Current Liabilities (2016 - 2026)
Greater Cannabis Company (GCAN) posted quarterly Total Current Liabilities of $776464.0 for Q1 2026, down 23.05% year-over-year from $1.0 million in Q1 2025, and up 4.58% quarter-over-quarter from $742464.0 in Q4 2025.
Trafalgar International (GCAN) Total Current Liabilities (2016 - 2026) Analysis & Trends
Greater Cannabis Company's Total Current Liabilities history runs 11 years deep, the most recent figure standing at $776464.0 for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 23.05% year-over-year to $776464.0; the TTM figure through Mar 2026 stood at $776464.0 (down 23.05% YoY), while the FY2025 annual figure was $742464.0, down 17.33% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $776464.0, up from $742464.0 in the prior quarter.
- The five-year high for Total Current Liabilities was $1.1 million in Q3 2025, with the low at $742464.0 in Q4 2025.
- The 5-year median for Total Current Liabilities is $860874.0 (2024), against an average of $897704.7.
- The sharpest annual moves came in 2022 and 2026: Total Current Liabilities soared 44.13% in 2022, then retreated 23.05% in 2026.
- Greater Cannabis Company's Total Current Liabilities stood at $825277.0 in 2022, then gained by 1.0% to $833508.0 in 2023, then gained by 7.74% to $898058.0 in 2024, then slipped by 17.33% to $742464.0 in 2025, then grew by 4.58% to $776464.0 in 2026.
- Business Quant data shows GCAN's Total Current Liabilities at $776464.0 in Q1 2026, $742464.0 in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 1.79 Bn |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | 776,464.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 776,464.00 |
| Dec 31, 2025 | 742,464.00 |
| Sep 30, 2025 | 1.13 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.01 Mn |
| Dec 31, 2024 | 898,058.00 |
| Sep 30, 2024 | 860,874.00 |
| Jun 30, 2024 | 833,993.00 |
| Mar 31, 2024 | 839,333.00 |
| Dec 31, 2023 | 833,508.00 |
| Sep 30, 2023 | 856,570.00 |
| Jun 30, 2023 | 881,605.00 |
| Mar 31, 2023 | 848,618.00 |
| Dec 31, 2022 | 825,277.00 |
| Sep 30, 2022 | 862,190.00 |
| Jun 30, 2022 | 965,767.00 |
| Mar 31, 2022 | 998,504.00 |
| Dec 31, 2021 | 861,999.00 |
| Sep 30, 2021 | 782,506.00 |
| Jun 30, 2021 | 670,049.00 |